Company intelligence / Profile preview

TheraPanacea

Paris, France

Ownership: Private
Employees: ~51
Development stage: Other

Overview

TheraPanacea’s AI-powered ART-Plan™ platform is CE-marked and FDA-/TGA-cleared, in commercial use at over 300 centers in Europe (and globally), with over 1.5 million patients treated. Clinical results show significant workflow acceleration and quality improvement in cancer radiotherapy, with biomarker/omic platforms poised for market deployment in neurology and precision medicine.[1][2][4][6]

Therapeutic areas: OncologyNeurology
Modalities: DeviceNon-pharmacological therapyArtificial intelligence-based diagnostic and therapy planning software
Industry: Digital Health Medical Devices

Partnerships

Biogen (strategic partnership for AI solutions and biomarker discovery in neurology)[2]Stingray Healthcare (AI radiotherapy workflow deployment partnership for European cancer centers)[4]

Beyond the preview

Go deeper on TheraPanacea.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TheraPanacea.

Explore the full profile